Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 397
- Registration Number
- NCT02136069
- Locations
- 🇮🇱
Chaim Sheba Medical Center; Pediatrics B North and Pediatric Endocrinology Unit, Tel Hashomer, Israel
🇭🇺Eszak-Kozep-budai Centrum, Uj Szent Janos Korhaz es Szakrendelo, Budapest, Hungary
🇭🇺Vasutegeszsegugyi Nonprofit KiemeltenKozhasznu Kft, Debrecen, Hungary
A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT02133937
A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 172
- Registration Number
- NCT02133508
- Locations
- 🇮🇹
A.O. Universitaria Policlinico Di Modena; Ematologia, Modena, Emilia-Romagna, Italy
🇮🇹Ospedale Provinciale Santa Maria delle Croci, Ravenna, Emilia-Romagna, Italy
🇮🇹Azienda Ospedaliera San Giuseppe Moscati, Avellino, Campania, Italy
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 401
- Registration Number
- NCT02132949
- Locations
- 🇵🇱
Wielkopolskie Centrum Onkologii; im. Marii Skłodowskiej-Curie, Poznan, Poland
🇵🇹Centro Clinico Champalimaud; Oncologia Medica, Lisboa, Portugal
🇺🇸Berkshire Medical Center, Pittsfield, Massachusetts, United States
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 444
- Registration Number
- NCT02131064
- Locations
- 🇺🇸
Cancer Care Assoc Med Group, Los Angeles, California, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
🇺🇸Hope A Women's Cancer Center, Asheville, North Carolina, United States
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1822
- Registration Number
- NCT02118584
- Locations
- 🇩🇰
Rigshospitalet; Afdeling for Tarmsvigt og Leversygdomme, København Ø, Denmark
🇭🇺Semmelweis Egyetem; Belgyogyaszati es Hematologiai Klinika, Budapest, Hungary
🇺🇸University of Alabama Medical Center, Birmingham, Alabama, United States
An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT02118597
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
- Conditions
- Wegener's Granulomatosis or Microscopic Polyangiitis
- Interventions
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT02115997
- Locations
- 🇮🇳
Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Department of Rheumatologz, Mumbai, Maharashtra, India
🇮🇳St. John's Medical College Hospital; Rheumatology, Bangalore, India
🇮🇳Medanta-The Medicity, Gurgaon, Haryana, India
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 310
- Registration Number
- NCT02108652
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇺🇸Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States
Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10228
- Registration Number
- NCT02106156